AbbVie [ABBV] vs Amgen [AMGN] Detailed Stock Comparison
AbbVie
NYSE
Loading...
Amgen
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: AbbVie wins in 11 metrics, Amgen wins in 9 metrics, with 0 ties. AbbVie appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | AbbVie | Amgen | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 104.87 | 22.62 | Amgen |
| Price-to-Book Ratio | -2,797.28 | 20.03 | AbbVie |
| Debt-to-Equity Ratio | -511.49 | 756.65 | AbbVie |
| PEG Ratio | -3.23 | 0.25 | AbbVie |
| EV/EBITDA | 15.60 | 12.20 | Amgen |
| Profit Margin (TTM) | 6.45% | 18.96% | Amgen |
| Operating Margin (TTM) | 37.52% | 32.73% | AbbVie |
| EBITDA Margin (TTM) | 37.52% | 32.73% | AbbVie |
| Return on Equity | 112.85% | 99.14% | AbbVie |
| Return on Assets (TTM) | 8.87% | 7.51% | AbbVie |
| Free Cash Flow (TTM) | $17.83B | $10.39B | AbbVie |
| Dividend Yield | 3.44% | 4.09% | Amgen |
| 1-Year Return | 12.41% | -16.83% | AbbVie |
| Price-to-Sales Ratio (TTM) | 6.67 | 4.26 | Amgen |
| Enterprise Value | $438.04B | $196.97B | AbbVie |
| EV/Revenue Ratio | 7.51 | 5.64 | Amgen |
| Gross Profit Margin (TTM) | 71.82% | 67.20% | AbbVie |
| Revenue per Share (TTM) | $33 | $65 | Amgen |
| Earnings per Share (Diluted) | $2.10 | $12.22 | Amgen |
| Beta (Stock Volatility) | 0.53 | 0.48 | Amgen |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
AbbVie vs Amgen Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| AbbVie | -0.85% | 2.72% | 9.92% | 13.47% | 2.96% | 21.68% |
| Amgen | -2.24% | -2.56% | -3.01% | -7.03% | -11.56% | 6.60% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| AbbVie | 12.41% | 51.55% | 142.28% | 256.62% | 561.58% | 561.58% |
| Amgen | -16.83% | 19.62% | 11.61% | 83.60% | 400.71% | 225.82% |
News Based Sentiment: AbbVie vs Amgen
AbbVie
News based Sentiment: POSITIVE
September was a pivotal month for AbbVie, primarily driven by the successful patent settlement for Rinvoq, which significantly extends market exclusivity and boosts future revenue potential. This, combined with positive clinical trial data and strategic acquisitions, strengthens the company's long-term growth trajectory and reinforces its position as a compelling investment.
Amgen
News based Sentiment: POSITIVE
Amgen demonstrated a strong financial performance in Q2 2025, exceeding earnings and revenue expectations. Coupled with positive clinical trial data and expanded FDA approval for Repatha, the company appears well-positioned for continued growth, despite mixed analyst sentiment and varied institutional investor activity.
Performance & Financial Health Analysis: AbbVie vs Amgen
| Metric | ABBV | AMGN |
|---|---|---|
| Market Information | ||
| Market Cap | $385.71B | $148.80B |
| Market Cap Category | Mega cap | Large cap |
| 10 Day Avg. Volume | 4,431,696 | 2,148,930 |
| 90 Day Avg. Volume | 4,744,749 | 2,112,570 |
| Last Close | $218.34 | $276.39 |
| 52 Week Range | $163.81 - $221.77 | $253.30 - $339.17 |
| % from 52W High | -1.55% | -18.51% |
| All-Time High | $221.77 (Sep 11, 2025) | $346.85 (Jul 22, 2024) |
| % from All-Time High | -1.55% | -20.31% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.07% | 0.09% |
| Quarterly Earnings Growth | -0.32% | 0.92% |
| Financial Health | ||
| Profit Margin (TTM) | 0.06% | 0.19% |
| Operating Margin (TTM) | 0.38% | 0.33% |
| Return on Equity (TTM) | 1.13% | 0.99% |
| Debt to Equity (MRQ) | -511.49 | 756.65 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $-0.10 | $13.80 |
| Cash per Share (MRQ) | $3.66 | $14.91 |
| Operating Cash Flow (TTM) | $19.28B | $12.01B |
| Levered Free Cash Flow (TTM) | $20.04B | $10.42B |
| Dividends | ||
| Last 12-Month Dividend Yield | 3.44% | 4.09% |
| Last 12-Month Dividend | $6.38 | $11.64 |
Valuation & Enterprise Metrics Analysis: AbbVie vs Amgen
| Metric | ABBV | AMGN |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 104.87 | 22.62 |
| Forward P/E | 18.15 | 13.37 |
| PEG Ratio | -3.23 | 0.25 |
| Price to Sales (TTM) | 6.67 | 4.26 |
| Price to Book (MRQ) | -2,797.28 | 20.03 |
| Market Capitalization | ||
| Market Capitalization | $385.71B | $148.80B |
| Enterprise Value | $438.04B | $196.97B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 7.51 | 5.64 |
| Enterprise to EBITDA | 15.60 | 12.20 |
| Risk & Other Metrics | ||
| Beta | 0.53 | 0.48 |
| Book Value per Share (MRQ) | $-0.10 | $13.80 |
Financial Statements Comparison: AbbVie vs Amgen
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | ABBV | AMGN |
|---|---|---|
| Revenue/Sales | $13.34B | $8.15B |
| Cost of Goods Sold | $4.00B | $2.97B |
| Gross Profit | $9.34B | $5.18B |
| Research & Development | $2.07B | $1.49B |
| Operating Income (EBIT) | $3.98B | $1.18B |
| EBITDA | $4.65B | $4.08B |
| Pre-Tax Income | $1.66B | $1.97B |
| Income Tax | $372.00M | $243.00M |
| Net Income (Profit) | $1.29B | $1.73B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | ABBV | AMGN |
|---|---|---|
| Cash & Equivalents | $5.18B | $8.81B |
| Total Current Assets | $27.68B | $26.93B |
| Total Current Liabilities | $36.40B | $23.01B |
| Long-Term Debt | $64.53B | $54.01B |
| Total Shareholders Equity | $1.46B | $6.21B |
| Retained Earnings | $-9.53B | $-27.14B |
| Property, Plant & Equipment | N/A | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | ABBV | AMGN |
|---|---|---|
| Operating Cash Flow | $2.26B | $1.71B |
| Capital Expenditures | $-235.00M | $-411.00M |
| Free Cash Flow | $1.40B | $980.00M |
| Debt Repayment | $-3.03B | $-2.50B |
| Common Stock Repurchase | $-961.00M | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | ABBV | AMGN |
|---|---|---|
| Shares Short | 15.40M | 11.80M |
| Short Ratio | 3.12 | 5.85 |
| Short % of Float | 0.01% | 0.02% |
| Average Daily Volume (10 Day) | 4,431,696 | 2,148,930 |
| Average Daily Volume (90 Day) | 4,744,749 | 2,112,570 |
| Shares Outstanding | 1.77B | 537.00M |
| Float Shares | 1.76B | 536.99M |
| % Held by Insiders | 0.00% | 0.00% |
| % Held by Institutions | 0.75% | 0.84% |
Dividend Analysis & Yield Comparison: AbbVie vs Amgen
| Metric | ABBV | AMGN |
|---|---|---|
| Last 12-Month Dividend | $6.38 | $11.64 |
| Last 12-Month Dividend Yield | 3.44% | 4.09% |
| 3-Year Avg Annual Dividend | $6.07 | $9.51 |
| 3-Year Avg Dividend Yield | 0.95% | 0.80% |
| 3-Year Total Dividends | $18.22 | $28.54 |
| Ex-Dividend Date | Apr 15, 2025 | Aug 22, 2025 |